These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12095312)

  • 41. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Heneghan M; Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD010966. PubMed ID: 37983082
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemical Chaperone 4-PBA Mitigates Tumor Necrosis Factor Alpha-Induced Endoplasmic Reticulum Stress in Human Airway Smooth Muscle.
    Delmotte P; Yap JQ; Dasgupta D; Sieck GC
    Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958799
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas.
    Tang Z; Liu L; Borlak J
    Clin Epigenetics; 2023 May; 15(1):89. PubMed ID: 37208732
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rhodopsin-associated retinal dystrophy: Disease mechanisms and therapeutic strategies.
    Zhen F; Zou T; Wang T; Zhou Y; Dong S; Zhang H
    Front Neurosci; 2023; 17():1132179. PubMed ID: 37077319
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nonretinoid chaperones improve rhodopsin homeostasis in a mouse model of retinitis pigmentosa.
    Vats A; Xi Y; Feng B; Clinger OD; St Leger AJ; Liu X; Ghosh A; Dermond CD; Lathrop KL; Tochtrop GP; Picaud S; Chen Y
    JCI Insight; 2022 May; 7(10):. PubMed ID: 35472194
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Toward Tumor Fight and Tumor Microenvironment Remodeling: PBA Induces Cell Cycle Arrest and Reduces Tumor Hybrid Cells' Pluripotency in Bladder Cancer.
    Rubio C; Avendaño-Ortiz J; Ruiz-Palomares R; Karaivanova V; Alberquilla O; Sánchez-Domínguez R; Casalvilla-Dueñas JC; Montalbán-Hernández K; Lodewijk I; Rodríguez-Izquierdo M; Munera-Maravilla E; Nunes SP; Suárez-Cabrera C; Pérez-Crespo M; Martínez VG; Morales L; Pérez-Escavy M; Alonso-Sánchez M; Lozano-Rodríguez R; Cueto FJ; Aguirre LA; Guerrero-Ramos F; Paramio JM; López-Collazo E; Dueñas M
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053451
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sodium 4-Phenylbutyrate Reduces Ocular Hypertension by Degrading Extracellular Matrix Deposition via Activation of MMP9.
    Maddineni P; Kasetti RB; Kodati B; Yacoub S; Zode GS
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576258
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus.
    Dunmore BJ; Jones RJ; Toshner MR; Upton PD; Morrell NW
    Cardiovasc Res; 2021 Sep; 117(11):2309-2325. PubMed ID: 33399862
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Small molecules restore the function of mutant CLC5 associated with Dent disease.
    Liu J; Sadeh TT; Lippiat JD; Thakker RV; Black GC; Manson F
    J Cell Mol Med; 2021 Jan; 25(2):1319-1322. PubMed ID: 33200471
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Protein Translocation Defect of MCT8
    Braun D; Schweizer U
    Eur Thyroid J; 2020 Sep; 9(5):269-280. PubMed ID: 33088796
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Second-Generation Pharmacological Chaperones: Beyond Inhibitors.
    Tran ML; Génisson Y; Ballereau S; Dehoux C
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32660097
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Small Molecules Restore Bestrophin 1 Expression and Function of Both Dominant and Recessive Bestrophinopathies in Patient-Derived Retinal Pigment Epithelium.
    Liu J; Taylor RL; Baines RA; Swanton L; Freeman S; Corneo B; Patel A; Marmorstein A; Knudsen T; Black GC; Manson F
    Invest Ophthalmol Vis Sci; 2020 May; 61(5):28. PubMed ID: 32421148
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease.
    Strub MD; McCray PB
    Genes (Basel); 2020 May; 11(5):. PubMed ID: 32414011
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine.
    Lopes-Pacheco M
    Front Pharmacol; 2019; 10():1662. PubMed ID: 32153386
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Regulation of CFTR Biogenesis by the Proteostatic Network and Pharmacological Modulators.
    Estabrooks S; Brodsky JL
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936842
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of the chemical chaperone 4-phenylbutyrate on secretion and activity of the p.Q160R missense variant of coagulation factor FVII.
    Andersen E; Chollet ME; Baroni M; Pinotti M; Bernardi F; Skarpen E; Sandset PM; Skretting G
    Cell Biosci; 2019; 9():69. PubMed ID: 31467667
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Shifting the balance of autophagy and proteasome activation reduces proteotoxic cell death: a novel therapeutic approach for restoring photoreceptor homeostasis.
    Qiu Y; Yao J; Jia L; Thompson DA; Zacks DN
    Cell Death Dis; 2019 Jul; 10(8):547. PubMed ID: 31320609
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine.
    Pranke I; Golec A; Hinzpeter A; Edelman A; Sermet-Gaudelus I
    Front Pharmacol; 2019; 10():121. PubMed ID: 30873022
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.